Detalhe da pesquisa
1.
In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry.
Lab Invest
; 104(3): 100309, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38135156
2.
Breast Cancer with HER2 IHC 2+ and Average HER2 Signals/Cell ≥ 6 and HER2/CEP17 Ratio < 2: A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.
Mod Pathol
; : 100530, 2024 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38810729
3.
HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
Histopathology
; 85(1): 3-19, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38443321
4.
Abnormal Uterine Involution May Lead to Atony and Postpartum Hemorrhage: A Hypothesis, With Review of the Evidence.
Pediatr Dev Pathol
; 26(5): 429-436, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37672676
5.
HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles.
Mod Pathol
; 35(8): 1075-1082, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35184150
6.
Interobserver agreement in the diagnosis of anal dysplasia: comparison between gastrointestinal and gynaecological pathologists and utility of consensus conferences.
Histopathology
; 80(4): 648-655, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34601750
7.
HER2-low breast cancers: Current insights and future directions.
Semin Diagn Pathol
; 39(5): 305-312, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35872032
8.
The relationship of myometrial histopathology (metropathy) to myometrial dysfunction and clinical manifestations.
Ann Diagn Pathol
; 57: 151902, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35123151
9.
Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study.
Mod Pathol
; 34(6): 1194-1202, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33536574
10.
Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.
Mod Pathol
; 34(1): 77-84, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32661297
11.
The pathogenesis of abnormal uterine bleeding in myopathic uteri.
Ann Diagn Pathol
; 52: 151726, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33706160
12.
Intratumoral heterogeneity of second-harmonic generation scattering from tumor collagen and its effects on metastatic risk prediction.
BMC Cancer
; 20(1): 1217, 2020 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33302909
13.
Applying the New Guidelines of HER2 Testing in Breast Cancer.
Curr Oncol Rep
; 22(5): 51, 2020 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32346807
14.
Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Mod Pathol
; 28(7): 921-31, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25932962
15.
Reconsidering "low-risk" criteria for breast cancer recurrence in hormone positive patients.
Breast J
; 25(3): 545-547, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30972823
16.
Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.
Hum Pathol
; 148: 51-59, 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740270
17.
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.
Cancers (Basel)
; 15(3)2023 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765765
18.
Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort.
Am J Clin Pathol
; 159(5): 484-491, 2023 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36856777
19.
HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category.
Hum Pathol
; 142: 34-41, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37979952
20.
The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing.
Cancers (Basel)
; 15(3)2023 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36765860